Ivermectin as a Potential Therapeutic Agent for COVID-19 – case studies
Wijaya et al., Cermin Dunia Kedokteran, 47:7, Dec 2020
Ivermectin as a Potential Therapeutic Agent for COVID-19 -case studies
Natalia Sisca Wijaya, Sidharta Salim
In December 2019, an outbreak of a novel coronavirus (SARS-CoV-2) started in Wuhan, China, and has since become a global threat to human health. To date, the worldwide response to the COVID-19 outbreak has been limited mainly to monitoring/containment. Several types of drug, as well as vaccination, are still under investigation and clinical trials worldwide. Recently, a study demonstrated ~5000-fold reduction in SARS-CoV-2 virus at 48h in cell culture after a single treatment of ivermectin. A clinical study at the University of Utah found that the administration of ivermectin during COVID-19 illness in hospitalized patients is associated with lower mortality and hospital length of stay. We report three confirmed cases of COVID-19 infection with significant improvement clinically and radiologically, with following treatment single dose of ivermectin
References
Guzzo, Furtek, Porras, Chen, Tipping et al., Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects, J Clin Pharmacol
Jaroslaw, Gorovits, COVID-19 alert
Lundberg, Pinkham, Baer, Amaya, Narayanan et al., Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis virus replication, Antivir. Res
Patel, Desai, Grainger, Mehra, Usefulness of ivermectin in COVID-19 illness
